Key facts
- Helicore Biopharma’s last known valuation is $98.0M (Jan 2025).
- It has raised $65.0M; the latest was Early Stage VC ($65.0M) in Jan 2025.
- Notable investors include OrbiMed, Wellington Management, Logos Capital, Longitude Capital, Versant Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Helicore Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Helicore Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Helicore Biopharma
Developer of a biopharmaceutical platform designed to discover novel antibody-based therapeutics to address obesity and related metabolic conditions. The company's platform offers a proprietary approach to neutralizing a hormone linked to fat accumulation, modular antibody engineering, and clinical-stage therapeutic development, enabling patients with obesity to access potential treatments that may improve metabolic health and appetite regulation.
- Sector
- Healthcare
- HQ
- San Mateo, CA, United States
- Founded
- 2023
- Employees
- 7
- Website
- helicore.com/
- Ownership
- Privately Held (backing)
Helicore Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Helicore Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Helicore Biopharma in its N-PORT filings yet. We sweep new filings monthly.